Marshall Stanton Sells 15,276 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 15,276 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $44.18, for a total value of $674,893.68. Following the completion of the transaction, the senior vice president directly owned 44,753 shares in the company, valued at $1,977,187.54. The trade was a 25.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Artivion Stock Performance

Shares of AORT stock opened at $46.85 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The stock has a market cap of $2.22 billion, a PE ratio of -111.55 and a beta of 1.65. The stock has a 50-day moving average of $43.24 and a 200-day moving average of $37.29. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.02. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. The business’s revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd boosted its stake in shares of Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after buying an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Artivion during the third quarter worth about $27,000. Smartleaf Asset Management LLC boosted its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the last quarter. State of Wyoming bought a new position in Artivion in the third quarter valued at approximately $80,000. Finally, Quadrant Capital Group LLC acquired a new position in shares of Artivion during the 3rd quarter worth approximately $92,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on AORT. Stifel Nicolaus lifted their target price on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Citizens Jmp increased their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Finally, Needham & Company LLC boosted their price objective on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Artivion currently has a consensus rating of “Moderate Buy” and an average price target of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.